Anophthalmia and microphthalmia
© Verma and FitzPatrick; licensee BioMed Central Ltd. 2007
Received: 25 July 2007
Accepted: 26 November 2007
Published: 26 November 2007
Skip to main content
We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
© Verma and FitzPatrick; licensee BioMed Central Ltd. 2007
Received: 25 July 2007
Accepted: 26 November 2007
Published: 26 November 2007
Anophthalmia and microphthalmia describe, respectively, the absence of an eye and the presence of a small eye within the orbit. The combined birth prevalence of these conditions is up to 30 per 100,000 population, with microphthalmia reported in up to 11% of blind children. High-resolution cranial imaging, post-mortem examination and genetic studies suggest that these conditions represent a phenotypic continuum. Both anophthalmia and microphthalmia may occur in isolation or as part of a syndrome, as in one-third of cases. Anophthalmia/microphthalmia have complex aetiology with chromosomal, monogenic and environmental causes identified. Chromosomal duplications, deletions and translocations are implicated. Of monogenic causes only SOX2 has been identified as a major causative gene. Other linked genes include PAX6, OTX2, CHX10 and RAX. SOX2 and PAX6 mutations may act through causing lens induction failure. FOXE3 mutations, associated with lens agenesis, have been observed in a few microphthalmic patients. OTX2, CHX10 and RAX have retinal expression and may result in anophthalmia/microphthalmia through failure of retinal differentiation. Environmental factors also play a contributory role. The strongest evidence appears to be with gestational-acquired infections, but may also include maternal vitamin A deficiency, exposure to X-rays, solvent misuse and thalidomide exposure. Diagnosis can be made pre- and post-natally using a combination of clinical features, imaging (ultrasonography and CT/MR scanning) and genetic analysis. Genetic counselling can be challenging due to the extensive range of genes responsible and wide variation in phenotypic expression. Appropriate counselling is indicated if the mode of inheritance can be identified. Differential diagnoses include cryptophthalmos, cyclopia and synophthalmia, and congenital cystic eye. Patients are often managed within multi-disciplinary teams consisting of ophthalmologists, paediatricians and/or clinical geneticists, especially for syndromic cases. Treatment is directed towards maximising existing vision and improving cosmesis through simultaneous stimulation of both soft tissue and bony orbital growth. Mild to moderate microphthalmia is managed conservatively with conformers. Severe microphthalmia and anophthalmia rely upon additional remodelling strategies of endo-orbital volume replacement (with implants, expanders and dermis-fat grafts) and soft tissue reconstruction. The potential for visual development in microphthalmic patients is dependent upon retinal development and other ocular characteristics.
Anophthalmia (OMIM 206900), Microphthalmia (OMIM 309700)
Anophthalmos, microphthalmos, nanophthalmos, nanophthalmia
The mean maximum axial lengths in the neonatal and adult human eye are approximately 17 and 23.8 mm respectively. Most of the post-natal growth of the eye occurs within the first three years with posterior segment expansion accounting for over 90% of post-natal growth. The International Clearinghouse for Birth Defects Monitoring Systems defines anophthalmia and microphthalmia as "anophthalmos/microphthalmos: apparently absent or small eyes. Some normal adnexal elements and eyelids are usually present. In microphthalmia, the corneal diameter is less than 10 mm, and the antero-posterior diameter of the globe is less than 20 mm" .
The birth prevalence of anophthalmia and microphthalmia has been generally estimated to be 3 and 14 per 100,000 population respectively, although other evidence puts the combined birth prevalence of these malformations at up to 30 per 100,000 population [2, 3]. Epidemiological data suggests risk factors for these conditions are maternal age over 40, multiple births [4, 5], infants of low birth weight and low gestational age . There is no predilection with regards to race or gender [4, 5]. Both anophthalmia and microphthalmia are more commonly bilateral; the exception appears to be isolated microphthalmia, which is usually unilateral . Microphthalmia is reported in 3.2 – 11.2% of blind children .
The precise pathogenesis of anophthalmia and microphthalmia remains unknown. Mann  suggested anophthalmia has its genesis early in gestation as a result of failure of development of the anterior neural tube (secondary anophthalmia) or optic pit(s) to enlarge and form optic vesicle(s) (primary anophthalmia). A third category, consecutive or degenerative anophthalmia was applied to cases where optic vesicles have degenerated and disappeared subsequent to formation. Observations of optic nerves, chiasm, and/or tracts with anophthalmia may indicate the regression of a partially developed eye rather than aplasia of the optic vesicle(s), a view supported by observations in an apparently anophthalmic orbit of extraocular muscle insertion into a fibrous mass, possibly representing an aborted eye . Following observations that the posterior segment of microphthalmic eyes are more affected than the anterior, Weiss and colleagues [10, 11] suggested that post-natal ocular growth is crucial and speculated that decreased size of the optic cup, altered proteoglycans in the vitreous, low intraocular pressure and abnormal growth factor production may all or in part have a bearing on the pathogenesis of simple microphthalmia; whilst inadequate production of secondary vitreous may result in complex microphthalmia. Some cases of microphthalmia may be associated with a cyst; these are believed to result from failure of the optic fissure to close .
Chromosomal abnormalities associated with anophthalmia/microphthalmia [55,7].
Duplication 3q syndrome (3q21-ter dup)
Learning difficulties, growth deficiency, hypertrichosis, craniosynostosis, cardiac defects, chest deformities, genital abnormalities, umbilical hernia
4p- (Wolf-Hirschhorn syndrome)
Growth deficiency, microcephaly, ocular hypertelorism, cranial asymmetry, learning difficulties, epilepsy, cleft lip/palate, anterior segment dysgenesis
Duplication 4p syndrome
Learning difficulties, epilepsy, growth deficiency, obesity, microcephaly, characteristic faces, genital abnormalities, kyphoscoliosis
Cryptophthalmos, cleft lip/palate, choanal atresia
Trisomy 9 mosaic syndrome
Joint contractures, congenital heart defects, prenatal growth deficiency, learning difficulties, micrognathia, kyphoscoliosis
Duplication 10q syndrome
Ptosis, short palpebral fissures, camptodactyly, learning difficulties, prenatal growth deficiency, microcephaly, heart and kidney malformations
13q-, 13 ring
Microcephaly, learning difficulties, bilateral retinoblastoma, cardiac defects, hypospadias, cryptorchidism
Trisomy 13 (Patau syndrome)
Holoprosencephaly, moderate microcephaly, coloboma, retinal dysplasia, cyclopia, cleft lip/palate, cardiac defects, genital abnormalities, 86% die within one year.
Midface hypoplasia, small stature, learning difficulties, hypotonia, nystagmus, conductive deafness, microcephaly, midface hypoplasia, genital abnormalities
Trisomy 18 (Edwards syndrome)
Polyhydramnios, single umbilical artery, small placenta, low foetal activity, learning difficulties, hypertonicity, hypoplasia of skeletal muscle, subcutaneous, adipose tissue, prominent occiput, low-set malformed auricles, micrognathia, cardiac defects
Large placenta with hydatidiform changes, growth deficiency, syndactyly, congenital heart defects, brain anomalies/holoprosencephaly
Ocular phenotypes associated with gene mutations linked to anophthalmia/microphthalmia.
Major (and selected less common) Human Ocular Phenotype(s)
Aniridia, (Peters anomaly, autosomal dominant keratopathy, foveal hypoplasia, optic nerve malformations, anophthalmia)
Anophthalmia/microphthalmia, (retinal dysplasia, optic nerve malformations)
Anterior segment dysgenesis, congenital primary aphakia
Autosomal dominant cataract, (microphthalmia)
PAX6, on chromosome 11p13, has been studied more extensively than most other eye genes. In humans, heterozygous loss-of-function mutations typically produce aniridia (OMIM 106210), a congenital panocular malformation associated with severe visual impairment; however PAX6 was also the first gene implicated in human anophthalmia . Although PAX6 mutations are an extremely rare cause of anophthalmia, there has recently been interest in a possible co-operative role between PAX6 and SOX2. Kondoh and colleagues  have shown that PAX6 and SOX2 co-bind to a regulatory element driving lens induction in the chick, which suggests that lens induction failure could be responsible for microphthalmia in patients with mutations in these genes . PAX6 and SOX2 interactions have since been shown to also drive lens induction in mammals through their action on the γ-crystallin gene (V van Heyningen, personal communication). Ultrasound bimicroscopy studies are required to determine if aphakia is commonly associated in microphthalmic SOX2 cases. As expected with genes expressed in the developing brain, patients with inherited PAX6 and SOX2 mutations exhibit CNS malformations in addition to dominantly inherited anophthalmia/microphthalmia [18, 9]. Interestingly mutations within the FOXE3 gene (on chromosome 1p32), associated with congenital primary aphakia (OMIM 610256), were observed in three siblings with microphthalmia; in all three cases the phenotype was believed to be secondary to lens agenesis .
Mutations in three genes with retinal expression are associated with anophthalmia/microphthalmia, possibly through failure of retinal differentiation. Heterozygous loss-of-function mutations of OTX2 (on chromosome 14q22, autosomal dominant inheritance) have been shown to be associated with a wide range of ocular disorders from anophthalmia and microphthalmia to retinal defects. CNS malformations and mental retardation are common in patients with OTX2 mutations [20, 9]. RAX, located on chromosome 18q21.32, is linked to about 2% of inherited anophthalmia/microphthalmia . Similarly, CHX10 mutations (chromosome 14q24.3) account for about 2% of isolated microphthalmia ; mutations in both genes characteristically presenting with recessively inherited phenotypes.
Two syndromes with broad phenotypes have been described recently in association with anophthalmia. GLI2 mutations had originally been described in the context of holoprosencephaly and polydactyly, however there has been a case reporting a missense mutation in a patient with asymmetrical genu and callosal agenesis co-existing with anophthalmia, thereby extending the phenotype . Anophthalmia with congenital heart defects, pulmonary abnormalities, diaphragmatic hernia and learning difficulties have been described in patients with mutations of the STRA6 gene . Our knowledge of genes associated with microphthalmia has also increased; complex microphthalmia in association with genetic cataracts has been attributed to mutations in the CRYBA4 gene . In addition to these putative genes, several loci have been identified with autosomal dominant microphthalmia mapping to 15q12-15 , autosomal recessive microphthalmia mapping to 14q32 [27, 28] and X-linked anophthalmia mapping to Xq27-28 .
Over the past several years, there has been an increased awareness of environmental factors associated with anophthalmia/microphthalmia. In 1993, the UK media reported clusters of anophthalmia and microphthalmia patients, speculating that these conditions may be connected to the pesticide Benomyl. Studies specifically designed to look at this issue found no definitive causal link [30–33]. The strongest evidence for environmental causes is for gestational-acquired infections, with rubella, toxoplasmosis, varicella and cytomegalovirus implicated [30, 34]. Other viruses in the herpes-zoster family have also been linked, as have parvovirus B19, influenza virus, and coxsackie A9 [35, 36]. Non-infectious causes have been postulated and include maternal vitamin A deficiency , fever, hyperthermia, exposure to X-rays, solvent misuse and exposure to drugs like thalidomide, warfarin and alcohol .
The diagnosis is usually based upon clinical and imaging criteria, and may be confirmed on histology if post-mortem is performed. Establishing a specific cause involves undertaking a comprehensive medical history, physical examination, family history, karyotyping and molecular genetic testing, imaging, renal ultrasonography, and audiology.
Anophthalmia can potentially be a difficult clinical diagnosis to make. Microphthalmia is usually diagnosed by inspection and palpation of the eye through the lids. The diagnosis is aided by measurements of corneal diameter, which ranges from 9–10.5 mm in neonates and 10.5–12 mm in adults. Microphthalmia with cyst usually presents with lower lid bulging. Electrodiagnostic tests may be valuable, particularly in cases of microphthalmia where retinal development has been unaffected. Eye examination of both parents should be undertaken and a careful family history of eye anomalies sought.
Because of the wide phenotypic spectrum associated with anophthalmia/microphthalmia, it is vital to assess these patients within multi-disciplinary teams that include paediatricians and clinical geneticists. Further investigations are dependent upon the clinical picture. If no syndrome is identified in infancy, further examination after another three or four years is desirable as many syndromes become more apparent by this age.
Ultrasound is most commonly used to determine the length of the globe in microphthalmic eyes.
Cryptophthalmos refers to completely fused eyelid margins, without lashes. These cases can be associated with both microphthalmia and microcornea. It is often bilateral and may be syndromic.
Cyclopia (total) and synophthalmia (partial) represent degrees of fusion of the optic vesicles thereby preventing the development of separate eyes. They correspond to neural maldevelopments incompatible with life.
In contrast to microphthalmia with cyst, which results from failure of the optic fissure to close, a congenital cystic eye may develop from failure of the optic vesicle to invaginate . At birth, the cystic eye may resemble anophthalmia, however with post-natal expansion, a bulge may appear behind the eyelids.
Genetic counselling is challenging both from the perspective of the extensive range of genes responsible for anophthalmia/microphthalmia and the wide variation in phenotypic expression. Only SOX2 has thus far been identified as a major anophthalmia/microphthalmia gene, with mutations primarily arising de novo. The picture is further complicated by observations of phenotypically normal parents carrying loss of function SOX2 or OTX2 mutations [41, 20]. Mosaicism and/or variable penetrance render prediction of recurrence risk difficult in these monogenic anophthalmia/microphthalmia cases. In general, if the mode of inheritance can be identified, then appropriate counselling is indicated. The empiric risk to siblings without a clear aetiology or family history is 10–15%, assuming inheritance accounts for half of cases with the other half occurring sporadically . Chromosomal abnormalities associated with anophthalmia/microphthalmia tend to be associated with distinct co-morbidities and give rise to specific syndromes. If a patient has a numerical chromosomal abnormality, the parents can be expected to be entirely normal whilst siblings are at a slightly increased risk of having a similar chromosomal abnormality, with similar or dissimilar phenotype . If a patient has a structurally unbalanced chromosomal constitution, the parents may have balanced chromosomal rearrangements and other siblings will be at a higher risk, though this will depend upon the specific rearrangement. If neither parent has any rearrangement, the risk to siblings is virtually negligible .
Cytogenetic studies are possible upon amniotic fluid foetal cells (usually withdrawn after 14 weeks of gestation) or on chorionic villus sampling specimens (at about 10 to 12 weeks). The power of these techniques in facilitating the pre-natal diagnosis of anophthalmia/microphthalmia was elegantly demonstrated by Guichet and colleagues (2004) . In a foetus with severe intrauterine growth retardation and bilateral anophthalmia on a 24-week ultrasound scan, they demonstrated a 46, XX, del(3)(q26.3q28) interstitial deletion of the long arm of chromosome 3 on 650 band karyotype. FISH analysis confirmed the interstitial deletion of 3q27 encompassing the SOX2 locus.
It is possible to detect anophthalmia/microphthalmia by early second trimester , though more recent reports place the limit at about 12 weeks with trans-vaginal ultrasound [44, 45]. Foetal eyes are best scanned in the coronal, axial and corono-axial planes and appear as symmetrical structures on either side of the nose. Lenses appear as smooth circular lines with hypoechogenic content on axial and coronal views. Eye size can be measured upon visualising the maximum coronal or axial planes of the orbit, and compared against established eye growth charts [46, 47].
where available can be used to supplement ultrasonography.
Detectable retinal function may be present in microphthalmia cases, particularly those associated with SOX2 mutations. It is important to refract these eyes and treat any underlying amblyopia. In unilateral cases, the 'good' eye must be protected and any visual deficit managed appropriately.
Surgical management can form the mainstay of anophthalmia/microphthalmia treatment. The globe triples in volume between birth and adolescence. The growth of the bony orbit reflects growth of the globe . Both congenital anophthalmia and microphthalmia result in a small volume orbit compared to age-matched controls , potentially leading to the appearance of hemifacial asymmetry. There is also evidence that enucleation (removal of the globe) produces a reduction in orbital volume in both children and adults [50, 51]. Reconstructive strategies rely upon the simultaneous management of both soft tissue hypoplasia and asymmetric bone growth .
Treatment is usually started early to maximise the overall development of these children. Mild/moderate microphthalmia is generally managed conservatively with insertion of a conformer (like a prosthetic eye but not painted), periodically increasing in size to allow for growth of the orbit. Treatment for severe microphthalmia and anophthalmia are usually started within weeks of life using conformers to enlarge the palpebral fissure, conjunctival cul-de-sac and orbit . Endo-orbital volume replacement using implants of progressively increasing size can be used to stimulate expansion of the developing bony orbit, usually after six months of age. Volume replacement using implants and expanders can also be supplemented by the use of dermis-fat grafts. Static orbital implants may need to be changed between three and five times before puberty and are associated with problems of wound dehiscence, extrusion or inadequate stimulation of bony growth. Expandable orbital implants were introduced as an efficacious means of stimulating bony growth and socket enlargement. Inflatable expanders are limited by difficulty maintaining orbital fixation for sustained expansion and controlling the direction of expansion, whilst self-expanding hydrogel spheres lose expansion force once fully hydrated. Orbital osteotomies are indicated in more severe cases [48, 52]. Ocular prostheses are used when the orbit has developed adequately, and are changed regularly with further orbital expansion. Conjunctival sac and lid reconstruction may be beneficial to the overall cosmetic effect. Microphthalmia with cyst is often treated around the age of five permitting the ophthalmic surgeon to take advantage of the orbital expansion properties of the cyst until the orbit is about 90% of the adult volume, whilst allowing removal for cosmetic reasons at about the time the child starts school. Surgical excision with preceding decompression is commonly performed, the cyst may also be aspirated but the recurrence rate is higher .
The potential for visual development depends upon the degree of retinal development and other ocular characteristics in microphthalmic patients. Therapy aims to maximise existing vision and enhance cosmetic appearances rather than improve sight.
The aetiology of anophthalmia/microphthalmia underlies the entire developmental biology of ocular formation and remains a field where our knowledge is increasing exponentially. Despite the progresses made, much work is still needed to understand the processes underlying these complex diseases, which are a significant cause of childhood blindness. Even if these processes are elucidated in the future, novel therapeutic approaches to prevent these conditions from occurring could still be precluded by very early ocular development in the foetus.
(central nervous system)
(magnetic resonance imaging)
(Online Mendelian Inheritance in Man ).
We gratefully acknowledge those patients who have permitted the usage of their clinical pictures to illustrate the manuscript.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.